# Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

> **NCT07424547** · PHASE1 · RECRUITING · sponsor: **Conjupro Biotherapeutics, Inc.** · enrollment: 386 (estimated)

## Conditions studied

- Cancer
- Solid Tumor Cancer
- Advanced Metastatic Cancer
- Prostate
- Small Cell Lung Cancer
- Ovarian Cancer
- Breast Cancer

## Interventions

- **DRUG:** SYS6043

## Key facts

- **NCT ID:** NCT07424547
- **Lead sponsor:** Conjupro Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2029-12
- **Final completion:** 2030-04
- **Target enrollment:** 386 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07424547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07424547, "Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07424547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*